Miplyffa Disease Interactions
There are 2 disease interactions with Miplyffa (arimoclomol).
Arimoclomol (applies to Miplyffa) liver disease
Moderate Potential Hazard, Moderate plausibility.
Arimoclomol has not been studied in patients with severe liver dysfunction (Child-Pugh C). No clinically significant changes in arimoclomol pharmacokinetics were observed in patients with mild or moderate liver dysfunction (Child-Pugh A or B) compared to those with normal liver function.
References (1)
- (2024) "Product Information. Miplyffa (arimoclomol)." Zevra Therapeutics, Inc.
Arimoclomol (applies to Miplyffa) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
The pharmacokinetic of arimoclomol have not been studied in patients with estimated glomerular filtration rate (eGFR) less than 15 mL/min. The recommended dosage of arimoclomol in combination with miglustat is lower in patients with eGFR 15 to less than 50 mL/min than the recommended dosage in patients with normal renal function; plasma arimoclomol levels were increased in patients with eGFR 15 to less than 50 mL/min compared to those with normal renal function. The recommended dosage of arimoclomol in combination with miglustat is the same in patients with eGFR at least 50 mL/min as for patients with normal renal function. During arimoclomol therapy, alternative measures that are not based on creatinine should be used to assess renal function (e.g., BUN, cystatin C, measured GFR); in clinical trials, increases in serum creatinine not associated with changes in glomerular function were observed with arimoclomol.
References (1)
- (2024) "Product Information. Miplyffa (arimoclomol)." Zevra Therapeutics, Inc.
Switch to consumer interaction data
Miplyffa drug interactions
There are 8 drug interactions with Miplyffa (arimoclomol).
Report options
More about Miplyffa (arimoclomol)
- Miplyffa consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.